Arabic Arabic English English French French German German
dark

Sarepta’s Second Muscular Dystrophy Drug Shows Greater Promise in Phase II

Sarepta Therapeutics announced Monday that its next-generation PPMO candidate, SRP-5051, showed promise in a Phase II trial when used as a treatment for Duchenne muscular dystrophy in patients amenable to exon 51 skipping. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Documentary Exposes the Alarming Truth — TV Puts Us In Hypnotic State and Suppresses Critical Thinking

Next Post

Standard Bariatrics® Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance

Related Posts
Total
0
Share